What is Tesamorelin? A Researcher's Guide to the GHRH Analogue

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that stimulates pituitary growth hormone (GH) secretion. It is one of the most clinically studied GHRH analogues and has attracted significant research interest for its effects on GH/IGF-1 axis modulation, visceral adipose tissue reduction, and metabolic regulation.

What is Tesamorelin?

Tesamorelin consists of the full 44-amino acid sequence of human GHRH(1-44) with a trans-3-hexenoic acid group conjugated to the N-terminus. This modification enhances stability against dipeptidyl peptidase IV (DPP-IV) degradation, extending its half-life compared to native GHRH while preserving full biological activity at the GHRH receptor.

Its primary receptor target is:

  • GHRH receptor (GHRHR) — expressed on pituitary somatotrophs; activation stimulates pulsatile GH secretion in a physiologically appropriate manner

Mechanism of Action

Tesamorelin acts as a full GHRHR agonist, stimulating pulsatile GH release from the anterior pituitary. This physiological pattern of GH secretion is important for research models — unlike exogenous GH administration, GHRH analogues preserve the natural pulsatile release pattern, which is associated with different downstream effects on IGF-1 production, lipolysis, and metabolic regulation.

GH released in response to Tesamorelin stimulates hepatic IGF-1 production and promotes lipolysis in visceral adipose tissue through hormone-sensitive lipase activation.

Why Tesamorelin is of Research Interest

Tesamorelin's ability to stimulate physiological GH release makes it a valuable research tool for GH axis studies. Key areas of ongoing research include:

  • Visceral adipose tissue and lipodystrophy models
  • GH/IGF-1 axis modulation and somatopause research
  • Metabolic syndrome and insulin resistance
  • Cognitive function and neuroprotection (IGF-1 mediated)
  • Cardiovascular risk factor research
  • Comparative GHRH analogue pharmacology

Tesamorelin vs. Ipamorelin/CJC-1295

Understanding Tesamorelin's position relative to other GH-stimulating peptides is important for research design:

  • Tesamorelin — GHRH analogue; acts at GHRHR on pituitary; physiological pulsatile GH release
  • CJC-1295 — GHRH analogue with DAC modification for extended half-life; sustained GH elevation
  • Ipamorelin — GHSR agonist (ghrelin mimetic); acts via different receptor pathway; selective GH release

Sourcing Tesamorelin for Research

Research-grade Tesamorelin should be sourced from suppliers providing batch-specific Certificates of Analysis (CoA) confirming purity (>98%), identity, and potency. Lyophilised formats offer optimal stability for laboratory storage.

At Aura Peptides, our Tesamorelin is supplied as a research-grade lyophilised peptide with full CoA documentation, available as single vials or in 10x bulk packs for high-volume research programmes.

For research purposes only. Not intended for human or veterinary use.

Back to blog